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Abstract
Objectives—To compare the proportion, timing and hazards of non-AIDS death and AIDS death 
among men and women who initiated HAART at different CD4+ cell counts to mortality risks of 
HIV-uninfected persons with similar risk factors.
Design—Prospective cohort studies.
Methods—We used parametric mixture models to compare proportions of AIDS and non-AIDS 
mortality and ages at death, and multivariable Cox models to compare cause-specific hazards of 
mortality, across levels of CD4+ cell count at HAART initiation (≤200 cells/μl: ‘late’, 201–350 
cells/μl: ‘intermediate’, >350 cells/μl: ‘early’) and with HIV-uninfected individuals from the 
Multicenter AIDS Cohort Study and the Women’s Interagency HIV Study. We used multiple 
imputation methods to address lead-time bias in sensitivity analysis.
Results—Earlier initiators were more likely to die of non-AIDS causes (early: 78%, 
intermediate: 74%, late: 49%), and at older ages (median years 72, 69, 66), relative to later 
initiators. Estimated median ages at non-AIDS death for each CD4+ cell count category were 
lower than that estimated for the HIV-uninfected group (75 years). In multivariable analysis, non-
AIDS death hazard ratios relative to early initiators were 2.15 for late initiators (P < 0.01) and 
1.66 for intermediate initiators (P = 0.01); AIDS death hazard ratios were 3.26 for late initiators (P 
<0.01) and 1.20 for intermediate initiators (P = 0.28). Strikingly, the adjusted hazards for non-
AIDS death among HIV-uninfected individuals and early initiators were nearly identical (hazard 
ratio 1.01). Inferences were unchanged after adjustment for lead-time bias.
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Conclusion—Results suggest the possibility of reducing the risk of non-AIDS mortality among 
HIV-infected individuals to approximate that faced by comparable HIV-uninfected individuals.
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Introduction
Treatment with HAART has increased life expectancies [1] and has lowered the share of 
AIDS-related mortality among HIV-infected populations [2]. Net effects of HAART on the 
hazards and timing of non-AIDS mortality in aggregate have been unclear. Associations 
between the degree of immune suppression and mortality from specific non-AIDS causes 
such as infections, myocardial infarctions and liver disease suggest that HAART, by 
restoring immune function, may reduce the risk of non-AIDS mortality.
Evidence has accumulated over time supporting HAART initiation at progressively higher 
CD4+ cell counts [3–11], and guidelines for clinicians have followed suit [12]. All-cause 
mortality risks remain elevated among HAART-treated patients relative to HIV-uninfected 
individuals [2], but there is still a pressing question as to whether the lifespan of optimally 
treated HIV-infected individuals may approach that of HIV-uninfected individuals [13]. 
Although most studies consider mortality in aggregate, non-AIDS-related mortality risks 
may also decrease when HAART is initiated at higher CD4+ cell counts [14]. Associations 
between CD4+ cell count at HAART initiation and the competing risks of non-AIDS-related 
and AIDS-related mortality remain unclear.
Materials and methods
Study population
The Multicenter AIDS Cohort Study (MACS) and the Women’s Interagency HIV Study 
(WIHS) are ongoing prospective cohort studies of HIV infection. Briefly, the MACS cohort 
is composed of homosexual and bisexual men from four sites in the United States, and the 
WIHS cohort is composed of women from six sites in the United States. The study 
population for this analysis included HIV-uninfected and HAART-exposed HIV-infected 
individuals. Only person-time after age 35 was included. The date of analysis was 1 January 
2011 and those alive at that date were administratively censored. Studies were approved by 
the Committees of Human Research of participating institutions and the executive 
committees of MACS and WIHS.
Definition of time scale
Age was the time scale for the analysis, with the origin at 35 years old. To prevent sparse 
events from driving model estimates, we considered person-time and outcomes observed 
between the ages of 35 and 70 years. Individuals entering the study after age 35 were 
handled using left-truncation methods to avoid bias due to late entry into the analytical 
period. We chose age as the time scale to provide a meaningful time origin for both HIV-
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uninfected and HAART-treated HIV-infected individuals and to provide the best possible 
control for age as a predictor of mortality.
We included both HIV-uninfected person-time and HIV-infected person-time following 
HAART initiation. Individuals could contribute person-time to both categories if they 
became infected with HIV during follow-up and were subsequently treated with HAART, 
with HIV-infected person-time prior to HAART initiation excluded from the analysis. Table 
1 summarizes the treatment of person-time in the analysis.
Definition of outcomes and exposures
The two outcomes of interest were death from AIDS and death from non-AIDS causes. 
Deaths among WIHS and MACS members were classified through a review of death 
certificate and National Death Index (NDI) records; deaths were considered AIDS-related if 
AIDS, an AIDS-defining illness, pneumonia or sepsis was listed as a contributing cause of 
death on the death certificate or the NDI. Deaths resulting from injury or poisoning (43 from 
the MACS and 49 from the WIHS) were treated as right-censored observations at the time of 
death, because such deaths were unlikely to be related to CD4+ cell count at HAART 
initiation and thus would have diluted effect estimates.
HAART initiators were classified into one of three categories defined by their CD4+ cell 
count at initiation (≤200 cells/μl: ‘late initiators’, 201–350 cells/μl: ‘intermediate initiators’, 
>350 cells/μl: ‘early initiators’). When the CD4+ cell count at the time of HAART initiation 
was unavailable, we used the last measurement prior to the HAART initiation date, 
excluding those for whom the time window exceeded 1 year.
We defined baseline values for exposure variables that were applicable to both HIV-infected 
and HIV-uninfected individuals, and that have established associations with mortality [15–
18]. Exposure variables were limited to those that were measured similarly between cohorts. 
Baseline was defined uniquely for each individual as the first study visit between ages 35 
and 70 years as either HIV-uninfected or HAART-treated. Our interest was in controlling 
for differences in mortality across groups defined by time-fixed covariates at baseline, rather 
than in the acute effects of time-varying exposures. We considered a wide range of baseline 
variables; those included in the final analysis are described below.
All covariates were defined dichotomously. Hepatitis B virus (HBV) infection was defined 
by a positive test for hepatitis B surface antigen at initial study visit, and hepatitis C virus 
(HCV) infection was defined by a positive viral RNA test for HCVat baseline (MACS) or at 
the initial study visit (WIHS). At analytical baseline, depressive symptoms were defined as a 
CESD score of more than 16 [19]; hypertension was defined as either SBP at least 140 
mmHg or DBP at least 90 mmHg; smoking and employment status (full-time, part-time or 
student) were measured by self-report. We also used cohort membership (MACS or WIHS) 
as a crude proxy variable to address sex and the other substantial differences in 
demographic, behavioural and socioeconomic traits between cohorts.
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Death from AIDS and death from non-AIDS causes are competing risks. To directly address 
the competing nature of these outcomes, we employed two statistical approaches. To obtain 
a fully parametric but minimally adjusted set of estimates, we fit mixture models [20] 
estimating both the proportion of individuals who experience each cause of death and the 
ages at death for each cause. We have previously described the details of this approach [2]. 
Let π be the proportion of HAART-treated individuals dying of non-AIDS causes by the 
upper limit of age (defined as 100), and (1 – π) be the the proportion dying of AIDS. Let 
S1(t) be the survival function for the π% dying of non-AIDS, and S2(t) be the survival 
function for the (1 – π)% dying of AIDS. The models simultaneously estimate the mixture 
parameter π and the survival functions S1(t) and S2(t), employing Weibull distributions of 
survival times with location β and scale σ such that the pth percentile is exp[β + 
σ{log(−log(1−p)}] for each cause of death. The parameters β, σ and π were allowed to vary 
by exposure category. Right-censored observations were treated as interval-censored with an 
upper limit of 100 years of age to ensure realistic estimates for ages at death [2]. A key 
advantage of these models is that they allow estimation of probability density functions on 
the age scale that are cause-specific and that graphically reflect the proportion of individuals 
dying of each cause. We calculated percentile differences in ages at cause-specific death by 
exposure category. Confidence intervals (CIs) for percentiles and differences in percentiles 
were calculated using the delta method [21].
As multivariable mixture models were impractical owing to the infrequency of mortality, we 
used multivariable proportional cause-specific hazards (PCSH) models [22]. The efficiency 
afforded by assuming proportional hazards allowed us to estimate cause-specific hazard 
ratios by CD4+ cell count category that were adjusted for important possible confounding 
variables. This approach also allowed testing for differential effects of an exposure across 
causes of death [22]. We started with a model containing only CD4+ cell count categories 
and study cohort (MACS/WIHS) and added covariates in a stepwise fashion.
In the mixture models, the likelihood function incorporated uncertainty regarding cause of 
death among deaths classified as ‘unknown’ because of either missing or equivocal cause of 
death information from death certificates or the NDI; this approach does not require the 
assumptions of alternative approaches based on cause-specific hazards [23] or subhazards 
[24]. In the PCSH models, we used multiple imputation methods to reclassify unknown 
deaths into AIDS and non-AIDS categories, an approach we described previously [2].
Relative to a hypothetical clinical trial in which 35-year-old individuals are followed from a 
common CD4+ cell count, these observational data are missing deaths and person-time that 
would have accrued prior to study entry in the intermediate and late initiator categories [25]. 
To address this lead-time bias, we employed a hybrid of two approaches [26,27]. For 
intermediate and late initiators with an observed HAART-naive CD4+ cell count more than 
350 cells/μl, we selected one such visit at random as the time at entry [26]. For those without 
such an observed visit, we multiply imputed the lead time using estimates from MACS data 
prior to HAART availability [27]. To derive these estimates, we fit mixtures of generalized 
gamma distributions, with the three outcomes defined as death from AIDS, death from non-
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AIDS and transition to a lower CD4+ cell count category. We then drew randomly from 
these conditional distributions to impute missing person-time for each individual. For the 
unseen events, we used estimates of π from the mixture models to determine the number of 
events, and random draws from the conditional distributions to determine the time to events. 
We performed 10 imputations, averaged the results, and appropriately adjusted the standard 
errors [28].
Statistical analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, North 
Carolina, USA) and R statistical software.
Results
Characteristics of the study population
Table 2 displays characteristics of the 6699 individuals who contributed person-time, 
stratified by HIV status and CD4+ cell count category at HAART initiation. There were 165 
deaths among HIV-uninfected individuals, and 341 AIDS deaths, 199 non-AIDS deaths and 
32 unknown deaths among HAART initiators.
Leading primary causes of non-AIDS death among hepatitis-free individuals were 
cardiovascular disease (38%), non-AIDS cancers (27%), pulmonary disease (10%) and liver 
disease (5%). Among those with hepatitis infection, leading non-AIDS death causes were 
liver disease (28%), non-AIDS cancer (24%), cardiovascular disease (15%), renal disease 
(8%) and pulmonary disease (7%).
HIV-uninfected individuals were more likely to be younger, MACS members, of white race, 
high school and college graduates, employed, nonsmokers, heavy drinkers, not obese, 
hypertensive and not depressed (P ≤ 0.01 for all comparisons) relative to HAART initiators. 
HBV (P =0.046) and HCV were less prevalent (P <0.01) among HIV-uninfected individuals 
relative to HAART initiators.
Results from mixture models
Those with HBV or HCV infection had substantially lower proportions of non-AIDS death 
(46 vs. 68%, P <0.01) and lower median ages at non-AIDS death (HIV-uninfected: 67.0 vs. 
75.0, P <0.01; HAART initiators: 54.1 vs. 69.0, P <0.01) relative to those without viral 
hepatitis. The following results from mixture models (Fig. 1) exclude those with HBV or 
HCV infection.
Figure 1 displays estimated probability density functions from mixture models for (a) non-
AIDS death and (b) AIDS death stratified by HIV infection status and CD4+ cell count at 
HAART initiation. The proportion of non-AIDS death (for early, intermediate, and late 
groups: 78%, 74%, 49%) and the median ages at non-AIDS death (72.0, 68.6, 65.7) 
decreased with lower CD4+ cell counts at HAART initiation (Fig. 1a). All CD4+ cell count 
categories had lower median ages at non-AIDS death relative to HIV-uninfected individuals 
(each P <0.01). Similarly, the median ages at AIDS death (54.5, 52.4, 47.4) decreased with 
lower CD4+ cell counts at HAART initiation (Fig. 1b).
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Figure 1c and 1d use the conditional distributions from the mixture models to plot 
differences in age at non-AIDS death and AIDS death, respectively, by percentile (the 
reference category in Fig. 1c is HIV-uninfected individuals, and that for Fig. 1d is early 
initiators). Estimated median ages at non-AIDS death were lower than those for HIV-
uninfected individuals by 3.0 years (95% CI 0.6–5.4) among early initiators; by 6.4 years 
(95% CI 3.7–9.2) among intermediate initiators; and by 9.3 years (95% CI 6.4–12.2) among 
late initiators. Estimated median ages at AIDS death were lower than those for early 
initiators by 2.1 years (95% CI −6.1 to 10.3) among intermediate initiators and by 7.0 years 
(95% CI 0.9–13.2) among late initiators.
Results from proportional cause-specific hazards model
Table 3 displays results from a multivariable PCSH model. In addition to the CD4+ cell 
count category at HAART initiation, this model included study cohort (MACS/WIHS), 
HBV/HCV infection, smoking, depression, unemployment and hypertension. The estimated 
hazard ratio for non-AIDS death for the HIV-uninfected group relative to early initiators was 
1.01 (P =0.95). Relative to early initiators, intermediate initiators had hazard ratios of 1.66 
(P =0.01) for non-AIDS death and 1.20 (P =0.28) for AIDS death. Late initiators had higher 
hazard ratios: 2.15 (P <0.01) for non-AIDS death and 3.26 (P <0.01) for AIDS death. 
Estimated hazard ratios for all other covariates were above one, and all were statistically 
significant except WIHS membership for AIDS death. The hazard ratio for hepatitis was 
higher for non-AIDS death than for AIDS death (P <0.05).
To test the assumption that covariate effects were the same for HIV-uninfected individuals 
and for HAART initiators with respect to non-AIDS death, we also fit models with 
interaction terms between each exposure and HIV infection status; none of these interaction 
terms were statistically significant.
Adjustment for lead-time bias
Augmenting the data to address lead-time bias (via multiple imputation) with unobserved 
person-time and deaths resulted in an average additional 4666 person-years, 74 AIDS deaths 
and 35 non-AIDS deaths among late initiators, and an additional 2397 person-years, 17 
AIDS deaths and seven non-AIDS deaths among intermediate initiators.
Table 4 compares results from this approach relative to those obtained without adjusting for 
lead-time bias. Among intermediate initiators, the proportion of non-AIDS death increased 
from 74 to 78%, the median age at non-AIDS death increased from 68.6 to 69.4 years and 
the median age at AIDS death decreased from 52.4 to 48.9 years. Among late initiators, the 
proportion of non-AIDS death increased from 49 to 51%, the median age at non-AIDS death 
decreased slightly from 65.7 to 65.3 years and the median age at AIDS death increased from 
47.4 to 48.7 years.
Controlling for cohort and for hepatitis infection, adjustment for lead-time bias led to 
attenuation of hazard ratios among intermediate initiators from 1.69 to 1.54 (non-AIDS 
death) and from 1.21 to 1.15 (AIDS death). For late initiators, hazard ratios were attenuated 
from 2.15 to 2.08 (non-AIDS death) and from 3.30 to 2.83 (AIDS death).
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The results show a strong relationship between CD4+ cell count at HAART initiation and 
cause-specific mortality. Earlier initiators were more likely to die of non-AIDS causes, and 
at older ages, than later initiators. Moreover, results suggest that non-AIDS mortality 
hazards among early initiators may approximate those faced by comparable HIV-uninfected 
individuals. Unadjusted results from mixture models show lower ages at non-AIDS death for 
even early HAART initiators relative to HIV-uninfected individuals. However, relative to 
HIV-uninfected study participants, HAART-treated individuals had characteristics 
associated with higher mortality. In multivariable PCSH models controlling for predictors of 
both non-AIDS and AIDS mortality, we observed that early HAART initiators and HIV-
uninfected individuals had statistically indistinguishable hazards of non-AIDS death.
The results also highlight the substantially higher risks of mortality faced by individuals 
coinfected with HIV and hepatitis, as those infected with hepatitis B or C at baseline died of 
AIDS more frequently, and died of non-AIDS 15 years earlier than their hepatitis-free 
counterparts in both the MACS and WIHS cohorts. Disaggregating hepatitis infection in 
sensitivity analysis (not shown) showed remarkably similar hazard ratios in the 
multivariable model for HBV infection relative to HCV infection.
This study has several limitations. There were few deaths relative to the number of 
individuals surviving to the end of analysis, which testifies to the success of HAART. 
However, this fact precluded the use of multivariable mixture models and led to low 
statistical power. Infrequent mortality also limited the number of CD4+ cell count categories 
for analysis. Estimates derived from observational data assume no unmeasured confounding, 
which may in fact be present. We attempted to minimize confounding by indication by 
controlling for covariates that affect disease progression, but if individuals who initiated 
HAART had a worse prognosis than those who did not initiate HAART at the same CD4+ 
cell count and with the same values for measured covariates, results would likely 
underestimate any benefits of earlier initiation [29]. We were careful to interpret the results 
according to the baseline nature of covariates; in the absence of such interpretation, changes 
in covariate status after analytical baseline could result in some residual confounding.
Survival estimates conditioned on the type of outcome, as in median ages at death from the 
mixture models, apply to selected populations, as those who died of non-AIDS causes 
necessarily avoided AIDS death, and vice versa. Comparisons of these estimates are thus 
subject to selection. Nonetheless, they serve as a useful description of the distribution of 
cause-specific mortality in populations.
An important strength of the analysis lies in the comparison of HIV-infected individuals 
with an HIV-uninfected group drawn from the same population, rather than resorting to a 
comparison with the general population. For example, life expectancies in the United States 
stratified by hepatitis infection are not readily available. Even when data on important 
covariates in the general population are available, study participants may differ from the 
general population in determinants of mortality that are either unmeasured or measured 
imprecisely.
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Another strength of the study was the inclusion of both men and women followed by parallel 
studies with a common data coordinating centre. It is notable that the adjusted hazard ratio 
for non-AIDS death among women was a statistically significant value of 1.4, indicating that 
residual effects of the lower socioeconomic status of WIHS members were powerful enough 
to remain after adjustment for several important covariates, despite the well-established 
longer lifespans of women in the general population.
Using age as the time scale provided strong control for this important mortality determinant, 
permitted comparison with HIV-uninfected individuals and allowed estimation of cause-
specific life expectancies. The duration of follow-up time in the cohorts was considerable, 
allowing us to observe more long-term outcomes than would otherwise be possible. 
Although individuals contributed a maximum follow-up time of 26.7 years for MACS and 
16.2 years for WIHS, we were able to use late entry methods to incorporate observed 
mortality between the ages of 35 and 70 years. Furthermore, using interval censoring 
methods on individuals who exited the study period alive allowed us to make realistic 
inferences beyond the observed age range.
The competing risks methods permitted a rich and detailed examination of mortality. 
Mixture models allowed parametric characterizations of cause-specific mortality, permitting 
meaningful summary measures (e.g. years by which exposures shorten life expectancies, as 
in Fig. 1). Cause-specific hazards models allowed multivariable analysis and formal tests for 
coefficient homogeneity across outcome types. Handling unknown deaths via multiple 
imputation in the semi-parametric models allowed us to use observed deaths to inform 
classification, rather than relying on exclusion or sensitivity analysis [24]. We are comforted 
by the fact that, in sensitivity analyses in which we assigned all unknown deaths to either of 
the causes, our effect estimates were not substantially altered and our qualitative conclusions 
were the same. This gives us reason to trust that any misclassification of mortality would not 
have altered our conclusions considerably.
Finally, we believe that the methods we used to address lead-time bias edged us closer to 
results that would be obtained in a randomized clinical trial. The direction of change in the 
estimates depends on the balance between the number of deaths and the amount of person-
time added to each exposure category during adjustment. After adjustment, the results were 
similar both qualitatively and quantitatively, indicating that added lead time was largely 
compensated by the added deaths. This adjustment relies on the experience of MACS 
members from the pre-HAART era; if these are not representative of the MACS and WIHS 
cohorts in the HAART era, bias may be present. The approach also assumes that CD4+ cell 
counts among the early initiators are representative of CD4+ cell counts at the imputed entry 
times for intermediate and late initiators. Distributions were indeed similar, as the median 
CD4+ cell count for early initiators was 488 cells/μl, compared with 544 cells/μl for later 
initiators with prior CD4+ cell counts greater than 350 cells/μl, and 543 cells/μl for those 
relying on natural history estimates.
The similar hazards of non-AIDS death between HIV-uninfected individuals and early 
HAART initiators may be partially explained by the quality of healthcare received by early 
HAART initiators. Comprehensive healthcare delivery for HIV-infected individuals, where 
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effective, has been suggested as a model for even HIV-uninfected individuals [30]. The 
hazard ratio for AIDS death (1.2) was not significant for intermediate initiators relative to 
early initiators. This may be an issue of statistical power and/or confounding by indication, 
as previous work has demonstrated mortality benefits from initiating HAART prior to a 
CD4+ cell count of 350 cells/μl [10,11].
The study population includes individuals on HAART regimens dating back to 1996 and 
individuals (some exposed to pre-HAART therapies) who lived with HIV prior to HAART 
availability. As therapies have become less toxic and more effective over time, and as 
therapy management strategies have improved, it may be expected that individuals initiating 
HAART today face lower risks of mortality than those estimated in this study.
These results suggest that early HAART initiation may diminish the elevated risks of non-
AIDS mortality faced by HIV-infected individuals, risks that may be partly mediated by 
inappropriate immune activation and inflammation. There is reason to believe that the gap in 
non-AIDS mortality between HAART-treated individuals and HIV-uninfected individuals 
may continue to decrease, that is, that HIV-related non-AIDS death may decline further. 
Better therapy regimens and improved social support hold the prospect of improving the 
survival of all HAART initiators nearer to that of HIV-uninfected individuals.
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Cause-specific mortality by CD4+cell count at HAART initiation, compared to HIV-
negative individuals (a,b) Probability density functions for non-AIDS death (a) and AIDS 
death (b), stratified by CD4+ cell count at HAART initiation. Percentages represent 
proportion of all-cause mortality. (c,d) Differences in age at non-AIDS death (c) and AIDS 
death (d) by percentile, stratified by CD4+cell count at HAART initiation. Reference 
category for (c) is HIV-negative. Reference category for (d) is CD4+ cell count >350 cells/μl 
at HAART initiation. For example, at 50% decreased in Fig. 1c, the value of the blue dashed 
line (−3.0) represents the median age at non-AIDS death for the early initiators (72.0) minus 
the median age at death for the HIV-negative reference (75.0). 95% confidence intervals at 
25th, 50th and 75th percentiles calculated using the delta method. Numbers on x-axis are 
deciles (years of age at death) for the reference group.
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Table 1
Description of person-time in study population.
Person-time category Entry time Exit time Status at exit
HIV-negative Years after age 35 first seen as 
HIV-negative (= 0 if first seen 
younger than age 35)
Years after age 35 
last seen as HIV-
negative
0 = right-censored: became HIV-positive, or 
alive as of 1 January, or turned 70 years of age, 
or died of accidental cause.
HIV-positive, HAART-experienced Years after age 35 first seen 
after HAART initiation (= 0 if 
first seen younger than age 35)
Years after age 35 
last seen
1 = died (of non-AIDS cause).
0 = right-censored: alive as of 1 January or 
turned 70 years of age, or died of accidental 
cause.
1 = died of non-AIDS cause.
2 = died of AIDS.
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